FDA Approves Inluriyo for Advanced Breast Cancer Treatment
The FDA has approved Eli Lilly's Inluriyo, an oral treatment for ESR1-mutated advanced breast cancer, offering new hope for patients with treatment-resistant disease after successful clinical trial results.
The U.S. Food and Drug Administration (FDA) has granted approval to Eli Lilly's medication Inluriyo (imlunestrant), an oral drug designed to target and inhibit estrogen receptors in patients with specific types of advanced breast cancer. This approval is significant for adults diagnosed with estrogen receptor-positive, HER2-negative metastatic breast cancer that harbors ESR1 mutations, particularly in cases where the disease has progressed after at least one line of endocrine therapy.
Inluriyo, available in 200 mg tablets, is administered once daily and works by binding to, blocking, and promoting the breakdown of overactive estrogen receptors. This mechanism helps to slow the progression of the disease and offers an alternative for patients with treatment-resistant cancer. The drug's approval was based on findings from the Phase III EMBER-3 clinical trial, where 256 patients with ESR1-mutated metastatic breast cancer received Inluriyo or other endocrine therapies. Results demonstrated that Inluriyo reduced the risk of disease progression or death by 38% compared to standard therapies.
Additionally, Inluriyo significantly extended progression-free survival, with a median of 5.5 months versus 3.8 months for comparators such as fulvestrant or exemestane, achieving a hazard ratio of 0.62. Dr. Komal Jhaveri of Memorial Sloan Kettering Cancer Center, a lead investigator in the trial, highlighted the importance of this development, noting that ESR1 mutations are present in nearly half of hormone therapy-treated metastatic breast cancer cases and often lead to resistance against conventional treatments.
The introduction of Inluriyo offers a promising new option for patients facing this challenging diagnosis, combining demonstrated efficacy, a tolerable safety profile, and the convenience of oral administration. More details can be found in the official announcement from Eli Lilly and additional information about the trial results on the Lilly investor page.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
U.S. Cuts Global Vaccine Funding: The Role of Philanthropy and Its Challenges
The U.S. reduces its support for global vaccination programs, increasing reliance on philanthropy which faces sustainability and influence challenges. Discover the impact on global health efforts.
A Genetic Mutation May Have Increased Human Vulnerability to Cancer Compared to Chimpanzees
A recent study reveals that a human-specific genetic mutation in the Fas Ligand protein may contribute to increased cancer vulnerability compared to chimpanzees, offering new insights for immunotherapy strategies.
Enhancing AI Accuracy in Antibody Identification Through Challenging Negative Data
Innovative research shows that training AI models with challenging negative data significantly improves their ability to identify effective antibodies, boosting drug discovery and biomedical research.
New Dendritic Nanotubular Network Discovered in the Brain and Its Potential Role in Alzheimer's Disease
Scientists have identified new dendritic nanotubes in the brain that may contribute to the spread of Alzheimer's disease by transporting amyloid-beta proteins, opening new pathways for early intervention.